Brandywine Global Investment Management LLC Decreases Stock Holdings in Humana Inc. $HUM

Key Points

• Brandywine Global Investment Management LLC decreased its holdings in Humana Inc. by 4.3% in Q1, owning 192,760 shares valued at approximately $51 million as of its latest SEC filing.
• Institutional investors now own 92.38% of Humana's stock, with other major investors like Vanguard and Pzena Investment Management increasing their holdings during the same timeframe.
• Humana reported a net margin of 1.28% and earnings per share of $6.27 for the last quarter, missing analysts' estimates by $0.05 despite revenue exceeding expectations at $32.39 billion.

Brandywine Global Investment Management LLC lessened its stake in shares of Humana Inc. (NYSE:HUM - Free Report) by 4.3% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 192,760 shares of the insurance provider's stock after selling 8,672 shares during the period. Brandywine Global Investment Management LLC owned about 0.16% of Humana worth $51,004,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Revolve Wealth Partners LLC acquired a new stake in Humana in the 4th quarter valued at about $202,000. Raymond James Financial Inc. acquired a new position in shares of Humana during the fourth quarter worth about $26,720,000. Mariner LLC boosted its holdings in Humana by 4.0% during the fourth quarter. Mariner LLC now owns 13,461 shares of the insurance provider's stock worth $3,415,000 after buying an additional 517 shares in the last quarter. Canada Post Corp Registered Pension Plan purchased a new stake in shares of Humana in the fourth quarter valued at about $271,000. Finally, Insigneo Advisory Services LLC lifted its stake in shares of Humana by 17.3% during the fourth quarter. Insigneo Advisory Services LLC now owns 1,360 shares of the insurance provider's stock valued at $345,000 after buying an additional 201 shares during the period. 92.38% of the stock is owned by hedge funds and other institutional investors.

Humana Price Performance

Shares of HUM traded up $5.39 during midday trading on Friday, hitting $286.73. 1,738,591 shares of the company traded hands, compared to its average volume of 1,946,733. The stock has a 50-day moving average of $242.70 and a 200-day moving average of $253.24. The firm has a market cap of $34.49 billion, a P/E ratio of 22.01, a PEG ratio of 1.68 and a beta of 0.44. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.95 and a quick ratio of 1.95. Humana Inc. has a one year low of $206.87 and a one year high of $382.72.

Humana (NYSE:HUM - Get Free Report) last announced its quarterly earnings results on Wednesday, July 30th. The insurance provider reported $6.27 EPS for the quarter, missing analysts' consensus estimates of $6.32 by ($0.05). Humana had a return on equity of 13.67% and a net margin of 1.28%. The business had revenue of $32.39 billion during the quarter, compared to analysts' expectations of $31.85 billion. During the same period in the previous year, the business earned $6.96 EPS. The business's revenue was up 9.6% compared to the same quarter last year. As a group, sell-side analysts predict that Humana Inc. will post 16.47 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the stock. Raymond James Financial upgraded shares of Humana from a "market perform" rating to an "outperform" rating and set a $315.00 price objective on the stock in a research note on Thursday, May 1st. Bank of America decreased their price target on shares of Humana from $320.00 to $260.00 and set a "neutral" rating on the stock in a research note on Tuesday, June 17th. Piper Sandler cut their price target on Humana from $288.00 to $272.00 and set a "neutral" rating for the company in a report on Thursday, July 31st. Cantor Fitzgerald reiterated a "neutral" rating and issued a $290.00 price objective on shares of Humana in a research report on Thursday, May 1st. Finally, Wells Fargo & Company cut their price objective on Humana from $348.00 to $344.00 and set an "overweight" rating for the company in a report on Thursday. Seventeen analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to data from MarketBeat, Humana has a consensus rating of "Hold" and a consensus price target of $281.43.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.